


## CHANGING THE WORLD, ONE PATIENT AT A TIME™



- A clinical stage pharmaceutical company developing an Anti-Cancer treatment with light activated PhotoDynamic Compounds ("PDC") and their associated drug formulation.
- Fully launched Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study.
- Focused on becoming the next standard of care for treating NMIBC.

### Anti-Cancer Technology ("ACT") Development

2011

- Licenced TLD-1433 PDC – Drug for Anti-Cancer Therapy<sup>1</sup>
- Successful pre-clinical results for NMIBC

2016

- US patent protecting of unique PDC, TLD-1433<sup>2</sup>
- Commenced Phase Ib NMIBC Clinical Study in human patients
- Demonstrated PDC application in various cancer indications - Glioblastoma Multiforme (brain cancer)

2019

- Completed \$1.4 M private placement equity financing (January, 2019)
- Oversubscribed Prospectus Offering \$17 M (August, 2019)
- Successful results from Phase Ib - 67% Complete Response with 2 patients cancer-free for 540 days
- Currently enrolling and treating for Phase II NMIBC Clinical Study
- Submitted Investigational New Drug application to FDA (September, 2019)

2015  
2019

TSX Venture 50  
Company in  
Clean Technology  
& Life Sciences

540

Days cancer-free  
status achieved by  
2 patients in Phase  
Ib NMIBC study

67%

Complete  
Response rate in  
Phase Ib NMIBC  
study

2

Patients treated  
in Phase II  
NMIBC study, to  
date

3

Canadian oncology  
sites enrolled for  
Phase II NMIBC, to  
date

3+

Cancer indications  
evaluated in pre-  
clinical studies

12

Owned and  
Licensed Patents

34

Patents Pending,  
strengthening  
Intellectual Property

14+

Published  
Peer-Reviewed  
Pre-clinical Studies

\$1.1B

USD

Estimated target  
market<sup>3</sup>

\$50K -  
\$150K

USD

Willingness to pay for  
treatment<sup>4</sup>

\$17M

CAD

Latest capital  
raised



### Capital Structure on the Venture<sup>5</sup> TSXV:TLT; OTCQB:TLTF

Common Share Price: C\$ 0.23

Market Capital: C\$ 48 M

Shares Outstanding: 204,275,375


Warrants: 91,546,372

Options: 16,740,000



Shares Fully Diluted: 312,546,372

Insider Ownership: 5.2% (8.8% fully diluted)

52 Week Range: C\$ 0.20 - 0.60



**Drug + Laser Light Device = Anti-Cancer Treatment for NMIBC**  
(TLD-1433) (TLC-3200) 67% Complete Response rate at 540 days (Phase Ib)



<sup>(1)</sup> McFarland – Theralase Licence Agreement, Dated: September 11, 2011

<sup>(2)</sup> U.S. Patent Nos. 9,345,769 and 9,676,806 and Canadian Patent No. 2,883,068 patents for "Metal-Based Thiophene Photodynamic Compounds and Their Use"

<sup>(3)</sup> 2025 estimated bladder cancer market (US, France, Germany, Italy, Spain, UK & Japan). Source: Global Data: Bladder cancer market size to more than triple to over \$1.1 billion by 2025, April 2017.

<sup>(4)</sup> Willingness to pay per quality adjusted life year (QALY) for competitor drug, Pembrolizumab. Source: Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer, July 2018

<sup>(5)</sup> Stock information is provided by <https://web.tmxmoney.com>, as of October 23, 2019